

**Fiscal Year 2013 (FY13) Amyotrophic Lateral Sclerosis Research Program (ALSRP)  
Reference Table of Award Mechanisms and Submission Requirements**

| Award Mechanism  | PI Eligibility  | Key Mechanism Elements   | Funding   | Submission Deadlines  |
|--|---|--|---|---|
| <p><b>Therapeutic Development Award</b></p> <p><b>Go to:</b><br/> <a href="#">Program Announcement</a><br/><br/> <a href="#">General Application Instructions</a></p> <p>Grants.gov Funding Opportunity Number:<br/> <a href="#">W81XWH-13-ALSRP-TDA</a></p> | <p>Independent investigators at all academic levels</p> | <ul style="list-style-type: none"> <li>• Supports preclinical development of therapeutics for ALS</li> <li>• Specific focus areas include:               <ul style="list-style-type: none"> <li>◦ Development of high-throughput screens and model systems</li> <li>◦ Development of pharmacological agents up to IND submission</li> <li>◦ Pilot cGMP production or formulation/ stability studies</li> </ul> </li> <li>• Preliminary data are required, relevant to the phase of preclinical development</li> <li>• Clinical trials are <u>not</u> allowed under this mechanism</li> </ul> | <ul style="list-style-type: none"> <li>• The maximum period of performance is 3 years.</li> <li>• The maximum allowable funding for the entire period of performance is \$1,500,000 in direct costs.</li> <li>• More cost-effective studies not requesting the full funding amount are encouraged.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul> | <p><b>Pre-application:</b><br/> <b>June 5, 2013</b><br/>           5:00 pm Eastern Time<br/>           Pre-application is required; Application submission is by invitation only</p> <p><b>Application:</b><br/> <b>September 18, 2013</b><br/>           11:59 pm Eastern Time</p> |

| Award Mechanism   | PI Eligibility                              | Key Mechanism Elements  | Funding   | Submission Deadlines   |
|---|---|---|---|--|
| <p><b>Therapeutic Idea Award</b></p> <p><b>Go to:</b><br/> <a href="#">Program Announcement</a><br/><br/> <a href="#">General Application Instructions</a></p> <p>Grants.gov Funding Opportunity Number:<br/> <a href="#">W81XWH-13-ALSRP-TIA</a></p> | <p>Investigators at all academic levels</p> | <ul style="list-style-type: none"> <li>• Supports early-stage research relative to novel therapeutic development for ALS</li> <li>• Studies should be hypothesis-based but have a clearly defined impact on and relevance to therapeutic development for ALS</li> <li>• Innovation and impact are primary criteria</li> <li>• Preliminary data are <u>not</u> required</li> </ul> | <ul style="list-style-type: none"> <li>• The maximum period of performance is 2 years.</li> <li>• The maximum allowable funding for the entire period of performance is \$400,000 in direct costs.</li> <li>• Indirect costs may be proposed in accordance with the institution's negotiated rate agreement.</li> </ul> | <p><b>Pre-application:</b><br/> <b>June 5, 2013</b><br/> 5:00 pm Eastern Time<br/> Pre-application is required;<br/> Application submission is by invitation only</p> <p><b>Application:</b><br/> <b>September 18, 2013</b><br/> 11:59 pm Eastern Time</p> |